Novel Ileocecal Valve-Sparing Anastomosis in Laparoscopic Right Hemicolectomy
A Retrospective Cohort Study Evaluating the Safety and Clinical Efficacy of a Novel Anastomotic Technique for Restoring Ileocecal Valve Function During Laparoscopic Radical Resection of Right-Sided Colon Cancer
1 other identifier
observational
43
1 country
1
Brief Summary
This is a single-center retrospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The study aims to evaluate the safety and clinical efficacy of a novel anastomotic technique designed to reconstruct ileocecal valve (ICV) function during laparoscopic right hemicolectomy for right-sided colon cancer. Background: Standard right hemicolectomy necessitates resection of the ICV, a critical structure regulating ileocolonic transit and acting as a bacterial barrier. Its loss can lead to small intestinal bacterial overgrowth (SIBO), diarrhea, malabsorption, and reduced quality of life. While preserving the ICV is ideal when oncologically feasible, it's often unavoidable. This study proposes an innovative anastomosis technique ("Revolute Insert Side-End Ileocecal Valve Reconstruction" - "RISE anastomosis") to functionally reconstruct the ICV. Study Design: Population: 50 patients who underwent laparoscopic right hemicolectomy at the center, meeting inclusion/exclusion criteria (age 18-80, ASA ≤3, primary tumors in appendix, cecum, ascending colon, hepatic flexure, or proximal 1/3 transverse colon, complete data). Groups: Conventional Anastomosis Group (n=30): Standard side-to-side ileocolic anastomosis using a linear stapler. RISE anastomosis Group (n=20): Novel technique involving everting the ileal stump with sutures to create an artificial valve, then implanting it into an incision on the colonic wall and suturing it circumferentially. Primary Objective: Assess safety and feasibility of RISE anastomosis. Secondary Objective: Evaluate the clinical efficacy of RISE anastomosis on bowel function recovery. Key Outcomes: Safety (Primary): 30-day postoperative complications (anastomotic leak, bleeding, stricture), severe complications (Clavien-Dindo). Efficacy (Secondary): Time to first flatus, first defecation, first formed stool; Bristol stool scale; defecation frequency/urgency; incontinence rates; length of stay; reoperation/readmission rates. Other: Operative time, anastomosis time, blood loss, lymph node yield, inflammatory markers, follow-up assessments (contrast studies, endoscopy). Data Analysis: Data extracted from electronic medical records. Statistical analysis using SPSS 22.0 (χ² test for categorical data, t-test for normally distributed continuous data; significance p\<0.05). Ethics: Approved by the institutional ethics committee. Conducted in accordance with the Declaration of Helsinki and Chinese regulations. Patient privacy and data confidentiality are prioritized. Timeline: Patient data collection and analysis (Jun-Aug 2024); Statistical analysis and manuscript preparation (Sep-Dec 2024). Significance: This study investigates a potentially transformative surgical technique. If proven safe and effective, RISE anastomosis could significantly improve postoperative bowel function and quality of life for patients requiring ICV resection during right hemicolectomy, addressing a major unmet clinical need related to ICV loss.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2024
CompletedFirst Submitted
Initial submission to the registry
June 26, 2025
CompletedFirst Posted
Study publicly available on registry
July 31, 2025
CompletedJuly 31, 2025
July 1, 2025
2 months
June 26, 2025
July 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
30-day postoperative complications (anastomotic leak, bleeding, stricture), severe complications (Clavien-Dindo).
After the surgery, continuously record whether the patient has any adverse reactions until 30 days postoperatively, and score the severity of the adverse reactions according to the Clavien-Dindo classification.
from day1 to day30 after surgery
Secondary Outcomes (2)
Time to first flatus
from day1 to day7 after surgery
Time to first formed stool
from day1 to day30 after surgery
Other Outcomes (4)
Operative time
During the operation
Anastomosis time
During the operation
Blood loss
During the operation
- +1 more other outcomes
Study Arms (2)
RISE anastomosis
Following right hemicolectomy, the novel RISE-ICVR technique involves everting the ileal stump to create an artificial valve, implanting it into a colonic wall incision, and securing it with circumferential sutures.
Conventional Anastomosis Group
In contrast, the conventional approach uses a linear stapler to perform a side-to-side ileocolic anastomosis.
Eligibility Criteria
The patients who visited Xinqiao Hospital and were diagnosed with right-sided colon cancer
You may qualify if:
- American Society of Anesthesiologists (ASA) physical status classification of II-III.
- Patients newly diagnosed with tumors located in the appendix, ileocecal region, ascending colon, hepatic flexure, or the right one-third of the transverse colon, or those scheduled to undergo laparoscopic right hemicolectomy.
- No history of other gastrointestinal diseases (excluding intestinal polyps and gallstones).
- Willingness to participate in the study with signed informed consent.
- Complete clinical data available.
You may not qualify if:
- Presence of malignancies in other anatomical sites.
- Tumor invasion into adjacent organs.
- Presence of infectious or autoimmune diseases (e.g., Crohn's disease).
- Congenital or acquired metabolic disorders.
- Use of antibiotics or other microbiota-altering medications within one month before enrollment.
- Changes in surgical plan such that the resection does not include the ileocecal valve.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Weidong Xiao, MD
Second Affiliated Hospital of Army Medical University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of General Surgery, Clinical Professor
Study Record Dates
First Submitted
June 26, 2025
First Posted
July 31, 2025
Study Start
July 1, 2024
Primary Completion
August 30, 2024
Study Completion
December 30, 2024
Last Updated
July 31, 2025
Record last verified: 2025-07